Thank you for joining us in 2022!

Colorectal Cancer Immunotherapy

November 12, 2022, 3:05 pm -
3:40 pm
Biomarkers for effective treatment

Session Description

While colorectal cancer rates are dropping overall, a worrying trend is emerging: cases are rising in adults between the ages of 20 and 50, who are not screened regularly. Given the necessity of early detection for current treatments, there is a growing need for effective treatments in advanced cases. Immunotherapy for colorectal cancer can be effective, especially in cases where tumors show high microsatellite instability. Join medical oncologist Dr. Luis Diaz Jr. of Memorial Sloan Kettering Cancer Center for a discussion of biomarkers, immunotherapies, and what patients with colorectal cancer need to know. He will be joined by Dr. Andrea Cercek of Memorial Sloan Kettering Cancer Center to answer your questions about genetic and genomic testing, treatment options, and other topics in our live Q&A.


Andrea Cercek, MD

Memorial Sloan Kettering Cancer Center

Andrea Cercek, MD is a board-certified medical oncologist specializing in the treatment of patients with gastrointestinal (GI) cancers, particularly colorectal cancer (CRC), appendix cancer, and cholangiocarcinoma. Her research is focused on the development of novel systemic and regional therapies, including approaches based on tumor genomics, with the goal of improving outcomes while minimizing treatment-related toxicities. She is the founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer. This clinic — the first of its kind in the world — is dedicated solely to the specific needs of people under 50 who have CRC or other GI cancers.

Luis Diaz Jr., MD

Memorial Sloan Kettering Cancer Center

Dr. Diaz is a physician-scientist who leads the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. His teams provided the first definitive evidence for using circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease; and discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors. This research led to the historic first pan-tumor FDA approval for any solid tumors with this genetic lesion and the first cancer study that resulted in a 100% complete response rate.  He is the recipient of numerous recognitions for his work including the Waun Ki Hong Award for Outstanding Achievement in Cancer Research. He was also the leader of the SU2C Colon Cancer Dream Team, Editor-in-Chief of Cancer Discovery and is an elected member of the Giants of Cancer Care, the AACR Fellows Academy, the American Society of Clinical Investigation, and the American Academy of Physicians. In 2021, Dr. Diaz was appointed by President Joseph Biden to the National Cancer Advisory Board.